イリノイ州におけるリンパ腫の臨床試験
イリノイ州内の拠点で、リンパ腫に関する23件の研究が参加者を募集しています。
イリノイ州内の都市
公式研究テキスト（英語）
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07015242CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Lurie Children's Hospital-Chicago, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
被験者募集中第1/2相
12 Months – 21 Years · 全性別 · 2026/09/11更新 · NCT04870944Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Chicago
被験者募集中第3相
18歳〜18歳 · 全性別 · 2026/09/08更新 · NCT07509151A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- University of Illinois Cancer Center, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06624085Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- City of Hope - Chicago, Zion
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/09/03更新 · NCT04588922Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
- University of Chicago, Chicago
- Northwestern University, Evanston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07284433A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- University of Chicago Medical Center, Chicago
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT04104776A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- The David and Etta Jonas Center for Cellular Therapy, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/17更新 · NCT06528301A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Northwestern, Chicago
- University of Chicago, Chicago
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/04更新 · NCT07188558Mosaic Trial for Stem Cell Transplant Recipients
- Northwestern University Feinberg School of Medicine, Chicago
被験者募集中
18歳以上 · 全性別 · 2026/08/03更新 · NCT06960993DALY II USA/ MB-CART2019.1 for DLBCL
- Robert H Lurie Cancer Center, Chicago
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/13更新 · NCT04792489A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Call for Information (Investigational Site 0024), Chicago
被験者募集中第1/2相
6 Months – 17 Years · 全性別 · 2026/07/06更新 · NCT02332668A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Northwestern University, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/02更新 · NCT05131022Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Lurie Children's Hospital-Chicago, Chicago
- Advocate Children's Hospital-Oak Lawn, Oak Lawn
- Saint Jude Midwest Affiliate, Peoria
被験者募集中観察研究
全年齢 · 全性別 · 2026/05/18更新 · NCT01790152CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Northwestern Memorial Hospital, Chicago
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/16更新 · NCT03328078The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Illinois at Chicago Cancer Center, Chicago
被験者募集中第1/2相
12歳〜95歳 · 全性別 · 2026/04/15更新 · NCT04329728A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
- City of Hope Chicago, Zion
被験者募集中第2相
18歳以上 · 全性別 · 2026/03/27更新 · NCT06915246A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- The University of Chicago Medical Center, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/20更新 · NCT04830137CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/03/04更新 · NCT07294677Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
- University of Chicago Comprehensive Cancer Center, Chicago
被験者募集中
18歳以上 · 全性別 · 2026/02/20更新 · NCT05745285Avo In R/R And Previously Untreated MCL
- University of Chicago Medical Center, Chicago
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/01/21更新 · NCT04855695Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
- OSF Saint Anthony's Health Center, Alton
被験者募集中第3相健康なボランティア歓迎
18歳以上 · 全性別 · 2026/01/13更新 · NCT05006482Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2025/09/22更新 · NCT04234048ClinicalTrials.govより、2026/10/03時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。